We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

94 hedge funds and large institutions have $187M invested in Eiger BioPharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 17 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

176% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 17

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

54% more capital invested

Capital invested by funds: $122M → $187M (+$65.5M)

1% more funds holding

Funds holding: 93 → 94 (+1)

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

Holders
94
Holders Change
+1
Holders Change %
+1.08%
% of All Funds
1.93%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
18
Increased
47
Reduced
17
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.01M
2
ACP
Acuta Capital Partners
California
+$2.87M
3
MP
Mangrove Partners
Connecticut
+$2.59M
4
Goldman Sachs
Goldman Sachs
New York
+$2.31M
5
SCM
Soleus Capital Management
Connecticut
+$2.11M

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$2.86M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.84M
3
N
Nuveen
North Carolina
-$1.36M
4
CAM
Cormorant Asset Management
Massachusetts
-$1.13M
5
PAWC
P.A.W. Capital
Connecticut
-$590K
Name Holding Trade Value Shares
Change 		Change in
Stake
6CM
1
683 Capital Management
New York
$20.7M +$1.15M +3,895 +6%
BlackRock
2
BlackRock
New York
$18.9M +$1.02M +3,446 +6%
VC
3
Vivo Capital
California
$17.2M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$12.4M +$240K +814 +2%
MP
5
Mangrove Partners
Connecticut
$9.1M +$2.59M +8,801 +39%
Citadel Advisors
6
Citadel Advisors
Florida
$8.48M +$295K +1,000 +4%
IVM
7
InterWest Venture Management
California
$7.34M – – –
CAM
8
Cormorant Asset Management
Massachusetts
$6.72M -$1.13M -3,838 -14%
SCM
9
Soleus Capital Management
Connecticut
$5.95M +$2.11M +7,169 +53%
KCM
10
Knoll Capital Management
Florida
$5.06M +$491K +1,667 +11%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$4.8M +$3.01M +10,221 +159%
State Street
12
State Street
Massachusetts
$4.42M +$3.24K +11 +0.1%
Northern Trust
13
Northern Trust
Illinois
$3.72M +$646K +2,190 +20%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$3.36M +$245K +831 +8%
JP Morgan Chase
15
JP Morgan Chase
New York
$2.98M +$158K +535 +5%
PAWC
16
P.A.W. Capital
Connecticut
$2.88M -$590K -2,000 -17%
Goldman Sachs
17
Goldman Sachs
New York
$2.84M +$2.31M +7,842 +391%
ACP
18
Acuta Capital Partners
California
$2.81M +$2.87M +9,750 New
Two Sigma Advisers
19
Two Sigma Advisers
New York
$2.56M +$394K +1,337 +18%
DMK
20
David M. Knott
$2.53M – – –
DC
21
Davenport & Co
Virginia
$2.34M -$49.2K -167 -2%
Two Sigma Investments
22
Two Sigma Investments
New York
$2.14M +$108K +367 +5%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$2.09M +$1.4M +4,746 +189%
CCM
24
Copernicus Capital Management
California
$1.92M +$1.97M +6,667 New
SCM
25
Suvretta Capital Management
New York
$1.91M +$389K +1,320 +25%
1
2 3 4 5

EIGR Hedge Fund Activity: Q2 2020 in Review

94 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2020, worth a combined $187M — up 54% from $122M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new EIGR positions and 17 closed out — a net gain of 1 holder — while 47 added to existing stakes and 17 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $3.01M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $2.86M sold.

  • 94 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2020, up from 93 in Q1 2020.
  • Funds reported $187M of Eiger BioPharmaceuticals, Inc. stock for Q2 2020, up 54% quarter-over-quarter.
  • 18 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2020 and 17 closed out, a net change of +1 holder.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2020 was Adage Capital Partners, an estimated $3.01M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2020 was J. Goldman & Co, an estimated $2.86M sold.

Based on aggregated 13F filings for Q2 2020.